The Next Generation in the Treatment of Alzheimer's Disease

Reneural Therapeutics is a pre-clinical startup pioneering a novel, disease-modifying oral therapy to combat the root causes of Alzheimer’s Disease.

Our Challenge

Alzheimer's Disease is a devastating global health crisis affecting over 50 million people, with cases projected to double by 2050 without a medical breakthrough. The disease is driven by a complex pathological cascade, including the buildup of amyloid-β and tau proteins, which leads to inflammation, synaptic dysfunction, and irreversible neurodegeneration. The current therapeutic landscape is in its infancy with most treatments focus on "downstream" targets, attempting to manage pathologies after significant damage is done, rather than addressing the root cause. This leaves a critical unmet need for an "upstream" intervention that can halt the disease's progression.

Opportunity

Reneural Therapeutics is pioneering a first-in-class, disease-modifying oral therapy to combat the root causes of neurodegeneration. This is a high-conviction opportunity, at the right time, with the potential to transform the lives of millions.

Our Key Value Propositions

Reneural Therapeutics has the science, the strategy, and the team to deliver a best/first-in-class therapy in a space that needs true innovation.

Backed by a significant investment in discovery our our lead candidate, RN-077 is an upstream intervention targeting a key kinase to address multiple disease pathologies simultaneously, including tau and amyloid-β.